All In Biotech

Drug Trial Radar · NCT04538534

Nicardipine to Avoid Spasm in Trans Radial Percutaneous Coronary Intervention

Last checked: Nov 20, 2026Latest source record: Feb 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,500 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,500

Actual

Start

Nov 1, 2020

Primary completion

Feb 1, 2022

Study completion Feb 1, 2022

Sponsor

Lead sponsor
Pr. Semir NouiraAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 4, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Radial artery is the recommended route for percutaneous coronary intervention for it significantly reduces net adverse clinical events compared to the femoral approach. The success of the radial approach is therefore of a paramount importance. However, radial artery spasm (RAS) remains one of the major limitations of transradial approach (TRA) and the most frequent cause of TRA failure. Several recommendations has been issued to improve success rate when using the radial route. In the Tunisian difficult economic context, the use of low end equipment, the unavailability of nitroglycerine and calcium antagonist verapamil, has led to the general feeling that RAS and TRA failure has subsequently increased. The standard and only used protocol by the Tunisian interventional cardiologist, consists of administrating 1 mg isosorbide dinitrate through the arterial sheath immediately after radial arterial puncture, therefore limiting the options to prevent RAS. Nicardipine is the only injectable calcium antagonist available in Tunisia. Its spasmolytic action on radial artery has been well demonstrated when used in CABG. However, it has been very poorly investigated in trans radial percutaneous coronary intervention. Investigators believe that the concomitant use of nicardipine with isorbide might significantly reduce RAS and TRA failure when compared to isosorbide dinitrate only.

Conditions

  • Spasm Artery

Interventions

  • NicardipineDrug

    To compare the association of nicardipine and isosorbide dinitrate vs isosorbide dinitrate alone on the rate of occurrence of radial artery spasm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants in which radial artery spasm occurredTime frame: 24 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CHU Fattouma Bourguiba

    Monastir, Tunisia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.